Knobbe Martens Olson & Bear LLP

Intellectual Property Law

12790 El Camino Real San Diego CA 92130 Tel 858-836-9000 Fax 858-836-9001 www.kmob.com

Brenden S. Gingrich, Ph.D. 858-836-9118 Brenden.Gingrich@kmob.com

April 13, 2011

ATTN: Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re: Title: MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN-LIKE GROWTH FACTOR EXPRESSION

Letters Patent No. 7,803,781 Issued: September 28, 2010 Our Reference: FBRIC67.001A

Dear Sir:

Enclosed for filing is a Certificate of Correction in connection with the above-identified patent.

As at least some of the errors cited in the Certificate of Correction were incurred through the fault of the Applicant, enclosed is our check in the amount of \$100. Please charge any additional fees to our Deposit Account No. 11-1410.

Respectfully submitted,

Knobbe, Martens, Olson & Bear, LLP

my Right

Brenden Gingrich

Registration No. 60,295

Customer No. 20995

Enclosures

11054755/adk/041211

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

: 7,803,781

Page 1 of 2

APPLICATION NO.

: 10/789526

ISSUE DATE

: September 28, 2010

INVENTOR(S)

: Dobie et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On Page 2, Column 2, Line 6, Change "Clss" to --Class--.

In Column 1, Line 10, Change "26," to --28,--.

In Column 3, Line 18, Change "output; Gut:" to --output; Gut:--.

In Column 3, Line 54, Change "IGF-R" to --IGF-IR--.

In Column 6, Line 28, Change "888-91." to --888-91--.

In Column 6, Line 47, Change "IGF-R." to --IGF-IR.--.

In Column 13, Line 41, Change "that" to --than--.

In Column 14, Line 60, Change "processing" to --processing--.

In Column 15, Line 66, Change "(SURF)" to --(SuRF)--.

In Column 21, Line 24, Change "dodecandiol" to --dodecanediol--.

In Column 21, Line 35, Change "indomethicin," to --indomethacin,--.

In Column 24, Line 66, Change "distearolyphosphatidyl" to --distearoylphosphatidyl--.

In Column 26, Line 10, Change "ribivirin," to --ribavirin,--.

In Column 26, Line 19, Change "factorl" to --factor--.

In Column 27, Line 19, Change "N-4" to --N⁴--.

In Column 27, Line 21, Change "2-deoxy-N-4" to --2'-deoxy-N⁴--.

In Column 27, Line 41, Change "amdite)," to --amidite),--.

In Column 29, Line 24, Change "2' hydroxyl." to --2'-hydroxyl.--.

In Column 30, Line 66, Change "spetrophotometrically" to --spectrophotometrically--.

In Column 34, Line 45, Change "Institute" to --Institute--.

In Column 36, Line 47, Change "geneotype" to --genotype--.

In Column 39, Line 26, Change "DATP," to --dATP,--.

MAILING ADDRESS OF SENDER:

Brenden Gingrich KNOBBE, MARTENS, OLSON & BEAR, LLP 2040 Main Street, 14th Floor Irvine, California 92614

DOCKET NO. FBRIC67.001A

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

: 7,803,781

Page 2 of 2

APPLICATION NO.

: 10/789526

ISSUE DATE

: September 28, 2010

INVENTOR(S)

: Dobie et al.

In Column 61, Line 42, Change "[125,]-hGH" to --[125]-hGH--.

In Column 245, Line 15, In Claim 9, change "ridge," to --bridge,--.

In Column 245, Line 22, In Claim 12, after "said" insert --compound--.

In Column 245, Line 26, In Claim 12, after "said" delete "antisense".

In Column 245, Line 28, In Claim 12, before "oligonucleotide" delete "antisense".

In Column 245, Line 41, In Claim 16, change "ridge," to --bridge, --.

11054586 041211

MAILING ADDRESS OF SENDER:

Brenden Gingrich KNOBBE, MARTENS, OLSON & BEAR, LLP 2040 Main Street, 14th Floor Irvine, California 92614

DOCKET NO. FBRIC67.001A